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ABSTRACT

PARTICLE SHAPE ENGINEERING FOR IMPROVED DRUG DELIVERY TO
PERIPHERAL LUNGS BY NON-INVASIVE ROUTE
Snehal Shukla

Inhalation of therapeutics has been gaining importance owing to immense
advantages offered by pulmonary route and have attracted significant advancements in the
pharmaceutical field. However, pulmonary drug delivery has been challenging because of
the complexity of the respiratory tract and the existing defense mechanism. The pulmonary
drug delivery has experienced advances in approaches and strategies to combat the existing
challenges by tailoring the physicochemical properties of the delivery carriers and enabling
both localized as well as systemic delivery. Pulmonary drug delivery is governed by
several biophysical parameters of the delivery carriers such as particle size, shape, density,
charge, and surface modifications. Although much attention has been garnered for other
parameters particle shape effects have been less likely explored. In this exploration we
studied the impact of particle shape on the aerodynamic properties, ability to escape
macrophage uptake and therapeutic effectiveness of particles against lung cancer.
Interestingly, the results of in-vitro lung deposition demonstrated improved aerodynamic
properties of the rod-shaped with high aspect ratio as compared to spherical particles.
Results of macrophage uptake demonstrate that high aspect ratio particles were internalized
less when compared to spherical particles. On the contrary, results of cellular uptake by
small cell lung cancer cells revealed preferential uptake of rod-shaped particles than
spherical particles. The results were further validated by in-vitro tumor simulation studies

wherein rod-shaped particles displayed enhanced anti-tumorigenic activity against spheres.
Moreover, the high aspect ratio particles also demonstrated diminished cardiotoxicity
activity; adverse effect of DOX limiting its therapeutic use. These results provide valuable
insights about influence of particle shape for designing inhalable therapeutics.
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1.0 Introduction
Respiratory diseases are defined as pathological condition which affect the
respiratory airways and other structure of lungs impacting their function [1]. They can be
classified based on the severity of disease as; 1) mild and self-limiting: common cold and
2) chronic and life-threatening: asthma, chronic obstructive pulmonary disease (COPD),
lung cancer etc. As per WHO (World Health Organization) report, respiratory diseases
account for ~30% deaths occurring worldwide [2]. The global burden of mortality due to
respiratory diseases has been contributed significantly by lower respiratory infections, lung
cancer and COPD accounting ~16.2 million deaths [2]. Pulmonary drug delivery has been
serving as first-line treatment for several respiratory diseases since the 20th century.
Characterized by large surface area (~100 m2 in adult humans), extensive blood capillary
network, very thin absorptive mucosal membrane and air-blood interface facilitating
increased permeation, enhanced absorption and improved pharmacokinetics of inhaled
therapeutics, pulmonary delivery offers diverse advantages [3,4]. Significance of
pulmonary delivery also involves features such as overcoming first pass metabolism,
limited degradation of therapeutics , reduced side effects, increased localized concentration
and enhanced therapeutic effect with only a fraction of dose [5,6]. For example, salbutamol
when given orally requires an oral dose of 2 mg to 4 mg while only 0.1mg-0.2 mg dose is
required upon inhalation to provide the same therapeutic effect [7]. Similarly, in a
comparative clinical study performed in healthy men, difference in pharmacokinetics of
oral vs. inhaled terbutaline was observed wherein inhalation of drug resulted into ~3 folds
increase in bioavailability of the drug as compared to oral administration [8].
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Local delivery to lungs have been widely explored for treatment of pulmonary
diseases and advances has been made over decades to develop efficient lung delivery
systems. Development of modern inhalation devices such as nebulizers, dry powder
inhalers and metered dose inhalers have improved the delivery of therapeutics to lungs.
Commercially available inhalation products for such as Advair® (Fluticasone and
Salmeterol), Symbicort® (Budesonide and Formoterol), Triohale® (Ciclesonide,
Formoterol and Tiotropium), TOBI® (Tobramycin), Colobreathe® (Colistimethate) have
perceived the success of pulmonary drug delivery for treatment of asthma, COPD, and
bacterial infections [9]. Recent FDA approval of Arikayce® inhalation suspension
comprising of amikacin encapsulated liposomes have paved the path for amalgamation of
nanotechnology with traditional pulmonary delivery methods [10]. Despite these
advancements, pulmonary delivery systems suffers several limitations such as short halflife, rapid elimination and low dose deposition impacting bioavailability followed by
frequent dose administration thereby passively impacting patient compliance [11,12]. To
address these issues, it is essential to understand the anatomical challenges existing and
tailor the biophysical parameters accordingly to design inhalable carriers which could lead
to development of optimized efficient carrier systems.
1.2 Physiological structure of the respiratory tract- A brief overview
The anatomical structure of human respiratory tract influences the flow passage of
air subsequently impacting the orientation and deposition of inhaled particles. The
respiratory tract is divided into two parts: 1) the upper respiratory tract consisting of nose,
nasal cavity and pharynx which is responsible for transporting air from external
environment to the sites of gas exchange and 2) the lower respiratory tract comprising of
2

larynx, tracheobronchial region and alveolar region which are involved in gas exchange
[13]. Pulmonary airway structure originates from the oro-pharynx region followed by
larynx and trachea. The trachea is fused with the larynx and enters in each side of lungs as
primary bronchi which divides into bronchioles paving the pathway for the air to reach the
respirable region in lungs [14]. The bronchioles branch into primary bronchioles,
secondary bronchioles, and respiratory bronchioles. Respiratory bronchioles terminate into
alveolar region comprising of alveolar ducts and alveolar sac [15]. The bronchi and
bronchioles are responsible for conducting the air to the alveolar region where the gas
exchange takes place. About 480 million alveoli are present in an adult lung and each
alveolus is lined with extensive pulmonary capillary resulting into huge surface area of 70140 m2 being available at the air-blood barrier for the exchange to take place [16,17].
In terms of cellular composition, respiratory tract is formed by continuous layer of
epithelial cells which are designed to perform specific functions such as: providing barrier
for protection against harmful agents, muco-ciliary clearance, secrete protective substances
to destroy the external agents and modulate immunogenic responses [18]. The epithelium
layer of the respiratory tract is shown to be possess about 40 different cells for
accomplishing successful respiration, indicating the complexity and heterogeneity as it
progresses from the trachea to the alveolar region as seen in Figure 1 [14,19]. The airway
epithelium in the conducting airways (trachea and bronchi) is pseudostratified and
columnar comprising of goblet cells (secreting mucus), basal cells and ciliated cells
(causing muco-ciliary escalation). The apical membrane of the cells have tight junctions
thereby providing a tight physical barrier for the entry of pathogen [20]. The conducting
airways epithelial region is also covered with pulmonary mucous lining. This mucus barrier
3

is composed of two different layers: the top layer is viscous gel like comprising of several
macromolecules having capacity to entrap wide range of inhaled particulates and is
continuously cleared by ciliary beating [21]. Mucus is comprised of water (95–97%),
mucin (glycoprotein), immunoglobulins, albumin, lysozyme, and lactoferrin [22]. While
the bottom layer is the periciliary layer which is a thin watery-sol layer composed of
minimal glycoproteins and proteins. The periciliary layer prevents mucus penetration in
the periciliary space and help in facilitating the ciliary activity [23]. In adults, the mucus
layer is reported to be renewed every 20 minutes and the mucus clearance rate is recorded
to be 3–25 mm/min [24]. Farther down the respiratory airways in the bronchiole region,
epithelial layer consist of simple columnar cells having shorter cilia which are more like
cuboidal shape and secretory club cells also known as Clara cells (Figure. 1) [14,20].
Moreover, the thickness of mucus lining which is ~ 10–30 μm in the tracheal region also
decrease progressively in the distal bronchioles to 2–5 μm [24].
The alveolar region has very a thin epithelial layer which is comprised of two types
of pneumonocytes: alveolar type I (AT-I) and alveolar type II (AT-II) cells. AT-I cells are
large, flat squamous cells covering ~90% of the alveolar surface and are responsible for
gas exchange due to their thin gas permeable membrane [20,25]. AT-II cells are small
cuboidal cells responsible for secretion of surfactants which lines the alveolar epithelium
providing the air-liquid interface [26]. The presence of surfactants help in reducing the
surface tension and thereby prevent the collapse of alveolar surface [27]. Pulmonary
surfactant comprises of a complex mixture of 92% lipids and 8% surfactant proteins (SP)
[28]. Amongst, the surfactant proteins SP-A and SP-D are large hydrophilic SPs also
known to induce immunomodulatory response by binding to the invading pathogen,
4

causing opsonization and further inducing phagocytosis [28,29]. While SP-B and SP-C are
the hydrophobic SPs responsible for maintaining the surfactant adsorption dynamics [30].
Resident alveolar macrophages present in the interstitial space are responsible for engulfing
any pathogen or debris of inhaled particulate [31].

Figure 1: Schematic representation of cells present in different regions of the respiratory
structure [14].
1.3 Understanding the Fate of particles upon entry into the respiratory tract
As can be seen in Figure 2 after inhalation, the particles first enters the central
lungs wherein they interact with the mucociliary layer. Depending on the physicochemical
properties the particles may either permeate the layer and reach the epithelia or may get
cleared from lungs via mucociliary clearance [32]. If the particles do not deposit and
successfully evade clearance in the central lung, they reach the peripheral lung (Figure 2).
The biophysical parameters of the particles may then determine the deposition of particles
in the conducting airways and its successful absorption [17]. The inhaled particles may get
5

internalized by alveolar macrophages depending on the particle properties which will be
discussed in detail in the following sections.

Figure 2: Fate of particles upon entering lung. The figure represents following steps 1)
deposition of particles on the airway epithelia 2) absorption/translocation of particle from
epithelia to blood circulation and 3) clearance by existing pulmonary barriers [26].
1.3.1 Step 1: Deposition of particles in respiratory tract
Upon entering the respiratory tract, inhaled particles are carried further in the
respiratory airways by the tidal air and mechanical forces such as gravity, inertia and
impulse collision along with the gas molecules resulting into deviation of their trajectories
from the streamlines causing them to deposit at varied site [33]. Inhaled particles in lungs
tend to deposit in the lungs based on following deposition mechanisms governed by their
physicochemical properties:
Inertial impaction: Larger particle (>5 µm) tend to deposit via inertial impaction wherein
the particles are incapable of streamlining themselves and deviate from the flow each time
when there is a bifurcation or change in the flow direction [34]. This deposition pattern is
observed in upper airways where the particles deviating from their trajectories impact the
site of deposition due to sudden change in the direction of air flow [35].
6

Gravitational sedimentation: Gravitational sedimentation refers to settling of particles
under the influence of gravity and is observed by particle within 1 to 8 µm range [33]. This
deposition mechanism has direct relationship with the particle size and residence time of
particles in the airways [35]. Gravitational sedimentation is commonly observed in smaller
airways and alveolar region where the residence time is high and the particles have less
distance to cover before reaching the airway walls [36].
Diffusion (Brownian motion): Diffusion is observed by particles of <0.5 µm which are
deposited into alveolar region by this deposition patter due to low air velocity in the region
[37]. Brownian motion of the particles occur upon collision with gas molecules resulting
into random motion of the particles [36]. This pattern of deposition has inverse relationship
with particle size where smaller the particle, higher is this deposition pattern observed
[35,38].
Interception: This deposition mechanism is observed for particle that are fiber-like,
elongated and have high length to width ratio (also known as aspect ratio). An increase in
elongation of particle results into increase in probability of deposition by this mechanism
[33,36,38]
Inhaled particles are deposited in different regions of the lung based on their size, shape,
density, charge, and surface properties of the particles. After deposition, the aerosol
particulates must overcome the existing pulmonary barriers to reach their targeted site. The
respiratory system eliminates the inhaled particles using pulmonary barriers depending on
the site of deposition (Figure. 2).
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1.3.2 Step 2: Drug dissolution and absorption in the lungs- Translocation of
particles
After deposition of particle on the respiratory surface, the particle must dissolve or
permeate the epithelia (bronchial or alveolar) for absorption [32]. Hydrophilic molecules
are rapidly absorbed and translocated to the systemic circulation; however, large
hydrophilic protein molecules post-deposition can interact with pulmonary surfactants
resulting into aggregation of particles hindering their absorption and eventually being
phagocytosed by alveolar macrophages [12]. On the contrary studies have reported that
lipophilic particles after deposition encounters with pulmonary surfactant which enhances
their permeability, solubility, and bioavailability [39,40]. Similarly, particles surface
modification also determines the translocation ability of the deposited particles. Cationic
and hydrophilic surfaces are reported to exhibit prolonged absorption and minimal
translocation when compared to neutral or negatively charged particles [41]. Choi et al.,
have evaluated the translocation of florescent labeled nanoparticles of varied size ranging
from 5 to 300 nm and functionalization after intratracheal administration in SpragueDawley (SD) male rats. Results illustrated that nanoparticles of < 36nm particle size
translocated from lung to lymph nodes, while extremely (<6 nm) small nanoparticles
rapidly translocated to lymph nodes and systemic circulation following which they were
cleared by kidneys. They have also demonstrated the impact of surface charge on
translocation of particle, wherein cationic charged particles inhibited pulmonary
translocation while neutral (polyethylene glycol coating) or zwitterionic (cysteine coating)
resulted into prompt translocation to various target organs [42]. Liu et al, assessed the invivo impact of size of radiolabeled particles (20 nm to 5 µm) on translocation from lungs.
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Large sized particles (~2 to 5 µm) were cleared by mucociliary clearance and translocated
to systemic circulation and other organs such as kidney, liver, spleen, thyroid, and heart.
On the other hand, smaller particles were found to have prolonged retention in lung and
translocated to blood, liver, and thyroid with reduced clearance [43]. Recently Buckley et
al., performed inhalation study on rats to evaluate the effect of particle size on clearance
and translocation of radioactive labeled iridium loaded nanoparticles ranging from 10 to
75 nm in size. They have reported low levels of particle size dependent translocation of
nanoparticles from lungs to organs such as kidney, liver, and brain with maximal deposition
occurring in kidney which subsequently is cleared [44]. Therefore, the physicochemical
properties of the inhaled particles governs the translocation of particles to the systemic
circulation, lymphatic system and or other target organs.
1.3.3 Step 3: Overcoming pulmonary barriers impacting the deposition of aerosol in
lungs.
A) Mucociliary clearance
Mucociliary clearance is the first line of defense mechanism offered in the conducting
airways. The principal of mucociliary clearance involves entrapment of inhaled particulates
in the thick mucus layer and escalating it by the ciliary beating towards larynx or pharynx
where they are either swallowed or coughed [45]. After deposition of particles in the
tracheobronchial region, the particles encounter with thin luminal surfactant lining
resulting into displacement of particle from the air interface to the underneath mucus layer
[46]. As the mucus layer is continuously moving proximally, the entrapped particles are
cleared immediately by either coughing or swallowing [3]. If the particles successfully
escape the mucociliary escalation, pulmonary dissolution of drug in the epithelial lining is
9

required for effective absorption of the inhaled drug. Hydrophilic drug molecules which
are freely soluble are rapidly absorbed while hydrophobic molecules are retained longer
and is highly susceptible to respiratory clearance [5]. Mucociliary clearance rate is known
to be increased with the increase in thickness of the mucus layer and the diameter of the
airways . Therefore, particles depositing in the proximal conducting airways are escalated
faster towards the larynx/pharynx resulting into their clearance [5]. Stahlhofen et al., has
demonstrated that particles larger than 6µm are easily entrapped in the mucus layer and are
subjected to mucociliary clearance while smaller particle are retained comparatively for
longer time [47,48]. However, Smith et al, demonstrated that particle size difference does
not impact the airway clearance of gold particles (dp 1.2 µm) and polystyrene (dp 5 µm)
administered using bonus inhalation and that both the particles displayed similar retention
in the lungs [49]. Furthermore, studies performed by Henning et al. revealed no significant
difference in the mucociliary clearance of particles evaluated for size ranging from 50 nm
to 6000 nm. On the contrary, material properties and surface chemistry of the particles were
found to impact the mucociliary clearance [50]. Mucociliary clearance serves as an
important defense mechanism against the invading agents, however, in some disease
conditions its function is impaired which affects the retention and efficacy of the inhaled
drugs [51]. Therefore, designing delivery carriers to impart prolonged residence and
improved therapeutic activity by tailoring their properties can be a promising strategy.
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B) Clearance by Alveolar Macrophages
Alveolar macrophages are present in the interstitial space in the alveolar region and are
recognized as the first line of cellular host defense [52]. Macrophages are phagocytic cells
which secret various cytokines or chemokines to activate the immune system against the
invading pathogen or particulate matter [53]. Alveolar macrophages display nonabsorptive clearance mechanism. These macrophages adhere to the inhaled particle by
either receptor binding or electrostatic interaction and engulf them. The engulfment can be
mediated by surface cavitation, vacuole formation or pseudopod formation [54].

Figure 3: Schematic representing the process of phagocytosis of particles by macrophages
[55].
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Figure 3 represents detailed phagocytosis process of macrophage. As can be
seen the first step of phagocytosis involves particles being present in the vicinity of
macrophages followed by attachment of the particle to the surface of macrophages. Upon
attachment of particle, pseudopod (cup-like structure) formation occurs via actin
remodeling for engulfment of the particles. After successful engulfment of particle,
phagosome formation occurs which later fuses with lysosome to form phagolysosome
(Figure 3). The phagolysosome degrades the particles by enzymatic action or acidic
environment and discharge the waste in the lymphatic system [55].
C) Clearance by Enzyme Degradation
Inhaled particles are also susceptible to degradation in lungs due to the presence of several
enzyme. Several enzymes are present in lung to maintain its physiological function and
serve as defense mechanism against the inhaled particles and xenobiotics along with
preserving the homeostasis [56]. Although, lung has relatively low level of enzyme activity
compared to liver, it is more comparatively more inducible [57]. Predominantly enzymes
belonging to cytochrome (CYP) P450 family such as flavin-containing monooxygenases
(FMO), monoamine oxidase (MAO), aldehyde dehyrogenase, NADPH-CYP450 reductase
is found throughout lungs [39]. Carboxylesterases responsible for hydrolysis of diverse
functional groups such as esters, amides, thiols and fatty acids are found to expressed in
human lungs [58]. Esterase, liable for cleavage of ester bonds are found extensively in
alveolar macrophage and in minimal amount in alveolar type I and II cells [4]. Proteases
responsible for degradation of proteins and peptides are present on the surface of bronchial
and alveolar epithelial cells [59].
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1.4 Essentials for Successful Pulmonary Delivery
For efficient delivery to lungs, inhaled delivery carriers must reach the desired site of action
which in most respiratory disease is peripheral lungs, and evade phagocytic uptake by
alveolar macrophages [1,19]. Advances in the field of pulmonary drug delivery have
identified several tunable bio-physical parameters that influences the drug delivery to the
lungs.

Parameters

such

as

particle

size[4–6],

density[7–9],

rigidity[10,11],

hygroscopicity[12–14] and surface chemistry[15–17] have been reported to govern the fate
and deposition of particles in lungs.
Despite the advancements, dug delivery to lungs suffers limitations such as low dose
deposition, rapid elimination of inhaled particles by existing defense mechanisms, short
half-life, impacting bioavailability and patient compliance [7,18]. The importance of
particle shape was illuminated after understanding the enhanced and prolonged retention
of respiratory disease-causing microorganisms such as Mycobacterium tuberculosis,
Hemophilus influenza, Legionella pneumophila and Pseudomonas aeruginosa in lungs
[20–22]. While inhaled particulate delivery carriers are known to be rapidly eliminated
from lungs, these microorganisms on the other hand demonstrate prolonged retention in
the peripheral lungs after overcoming the existing lung defense mechanisms, thus causing
severe to cause various respiratory diseases. It is interesting to comprehend that the shape
of these micro-organisms causing respiratory diseases in peripheral lung are known to be
aspherical or rod rod-like, shapes which is suggestive to play an important role in
enhancing their aerodynamic properties[23], and evading clearance by lungs’ defense
mechanisms [23,24].
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In addition to aspherical Additionally, microorganisms, rod-shaped, or fibrous particles
such as asbestos and carbon nanotubes are deposited in the alveolar region and result into
adverse health effects implying that particle shape enhances aerodynamic behavior of
particles [25,26]. Several computational fluid dynamic (CFD) studies have revealed the
deposition performance of fibers or elongated particles in lungs wherein they are reported
to orient themselves parallel to airflow and hence travel preferentially to the distal region
of lungs [27–29]. However, experimental respiratory deposition data or in-vitro deposition
behavior of such anisometric rod-shaped or fibrous particles has not been thoroughly
examined [30], . Thereby indicating the dire need to experimentally investigate the role of
particle shape further experimentally on aerodynamic behavior and peripheral lung
deposition of aspherical particles in lungs.
Along with particle deposition, cellular internalization is another paramount factor
deciding the therapeutic fate of particles in lungs. Several studies have highlighted the
details of particle shape and its role in phagocytic uptake wherein rod-shape or filamentous
particle being successful in evading the uptake by macrophage [31–33]. It has been shown
that not only the shape of particle but also the orientation of particle or target geometry
encountering the surface of cells determines their internalization of into target cells [31,34].
Target geometry of particles is defined by the contact angle wherein particles with high
curvature regions are known to escape the uptake by macrophages [32,34]. On the other
hand, studies have reported that non-spherical particles are readily internalized by various
cancer cells as compared to their counterparts [33,35,36]. In a recent study, by He and
Park, examined the influence of 20 different shapes and sized particles on the
internalization by cancer cells. Their results have reported that local interaction between
14

particle and cell surface determined the internalization fate of particles, and elongated
particles with sharper angular features were readily internalized [36]. Thus, fine fine-tuning
the particle shape of inhaled delivery carriers may serve as a potential strategy to address
the existing limitations of pulmonary drug delivery systems and improving their
therapeutic efficiency.
The aim of the present study is to explore novel strategy of particle shape fabrication
modulation for development of effective inhaled delivery carriers possessing peripheral
lung deposition with efficient aerodynamic properties and capability to evading
macrophagic uptake. We have utilized Doxorubicin hydrochloride (DOX) as a model drug
to evaluate the influence of particle shape on the therapeutic effectiveness of the delivery
carriers. The aerodynamic properties of the varied size and shaped particles was evaluated
using in-vitro lung deposition simulator, next generator impactor (NGI). Further,
therapeutic activity of various DOX-conjugated particles was assessed by systematic invitro studies performed on small cell lung cancer chosen as a model pulmonary disease.
Additionally, as DOX is known to be limited for its therapeutic use because of
cardiotoxicity, the influence of particle shape in overcoming this limitation of DOX was
also examined.
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2.0 Hypothesis
“Particle shape modification enables significant deep lung deposition with efficient
aerodynamic properties”.
To test this hypothesis, the following questions will be addressed in this exploration:
1.) Could the particles with varied shape be fabricated?
2.) Does particle shape influence the aerodynamic behavior?
3.) Does particle shape impact the uptake by macrophages?
4.) Could particle shape improve the efficacy of drug against lung cancer?
5.) Could particle shape reduce the toxicity of drug?
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3.0 Materials and Methods
3.1 Materials
Polystyrene microspheres of different sizes (0.5 µm, , 6.0 µm and 10µm) were
purchased from PolySciences, Inc. (Warrington, PA, USA). Poly (vinyl alcohol) (PVAfully hydrolyzed) was obtained from Sigma Aldrich (St. Louis, MO, USA). Doxorubicin
hydrochloride (DOX) was procured from LC laboratories (Woburn, MA, USA). Phosphate
Buffer saline (PBS) pH 7.5, dimethyl sulfoxide (DMSO) and HPLC grade solvents such as
acetonitrile and water were purchased from Fisher Scientific (Hampton, NH, USA).
Various other assay kits and other molecular biology grade reagents were obtained from
several sources which have been listed along with their respective methods.
3.2 Cell Culture
Murine macrophages RAW 264.7 cells, multidrug resistant human small cell lung
cancer (SCLC) cell line H69AR and rat cardiomyoblasts H9c2 cells were acquired from
American Type Culture Collection (ATCC) (Manassas, VA, USA). H69AR cells were
cultured in Roswell Park Memorial Institute (RPMI) 1640, while RAW 264.7 and H9c2
cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Corning Inc.,
Corning, NY, USA), supplemented with 10% fetal bovine serum (Atlanta Biologicals,
Flowery Branch, GA, USA), 1% sodium pyruvate and 1% penicillin-streptomycin
(Corning Inc., Corning, NY, USA) by incubation at 37°C under 5% CO2. 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and crystal violet were
obtained from Fisher Scientific (Hampton, NH, USA). Vectashield hardset mounting
medium kit with DAPI was procured from Vector Laboratories Inc. (Burlingame, CA,
USA).
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3.3 Particle Fabrication
Spherical particles were fabricated to rod-shaped particles using one dimension
stretching method as reported earlier with slight modifications [9]. As can be seen in
Figure 1A, carboxylated functionalized polystyrene particles of different sizes (0.5 µm,
6.0 µm and 10µm) were dispersed in poly-vinyl alcohol (PVA) film; and were subsequently
stretched to desired length in an oil bath using custom made apparatus.
3.3.1 Film preparation
Briefly, 5% PVA (~2 g in 30 ml of water) was dissolved in water at 85°C with
continuous stirring. After complete dissolution of PVA, 2% (w/v) glycerol was added as
plasticizer to the PVA solution. The resultant mixture was then allowed to cool and
spherical polystyrene particles (~0.75 mL) were added to this mixture. The mixture was
later carefully poured on a 13 × 13-cm petri plate to avoid entrapment of any air bubble in
the film. Resultant films were dried completely for ~48 hrs, and stored in a dry place until
further use.
3.3.2 Film stretching
The dried film was cut into sections of ~5 × 5 cm and mounted on the custom-made
stretchers [60,61]. The stretcher comprised of two aluminum blocks mounted on a screw.
After mounting the film on the blocks, the length of the film in between the two blocks was
measured which helped in determining the final distance for separation. The stretcher along
with the mounted film was immersed in hot mineral oil (~120°C) for 5 min and stretching
was performed by keeping the stretcher in the oil bath (Figure 4). Stretching of the film
was performed to 3 folds or 6 folds of the initial length of film mounted between aluminum
blocks to obtain rod shaped particles of varied lengths. Short rods (SR) were obtained upon
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stretching the films to 3 folds of its initial length while 6 folds stretching resulted into long
rods (LR) After stretching to the desired distance, film was cooled for 10 minutes before
unmounting from the stretcher.
3.3.3 Particle recovery
The stretched film was removed from the stretcher and cut into extremely small
pieces which were dissolved in water at 70°C. The particles were washed by centrifugation
at 10,000xg for 10 minutes with water. The washing was performed thrice to remove PVA
from the mixture. The recovered stretched particles were finally redispersed in 1 mL of
water and stored at 4°C until further use.

Figure 4: Schematic representation of fabrication of particles of varied shapes using the
stretching method.
3.4 Structural Morphology
Morphology of the fabricated particles were examined using Nova Nano SEM™
450 and Helios Nano Lab 660 (FEI, Hillsboro, Oregon, USA). Briefly, the particles were
dried on the SEM pin stub (Ted Pella, Inc., Redding, CA, USA) and then sputter coated
with palladium for 90s and imaged at 5 kV. The dimensions of particles were obtained by
measured 30 particles (n=3) from each of the obtained micrographs using Image J analysis
software.
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3.5 Conjugation DOX on Spherical and Stretched Particles
Conventional carbodiimide chemistry was used for conjugating carboxylate groups
on particles’ surface to the amine group of DOX resulting into formation of amide bond as
shown in Figure 5. Briefly, 1mg of particles were added to aqueous solution containing
excess

1-Ethyl-3-(3-dimethylaminopropyl)

carbodiimide

(EDC)

and

N-hydroxy

succinimide (NHS) and stirred for 3 hrs. at room temperature. This reaction allowed the
carboxylic groups to be activated. Particles were then centrifuged to remove the excess of
EDC and NHS followed by washing to ensure complete removal of the reagents. The
activated particles were then incubated with excess amount of DOX (1 mg) for 72 hrs.
Following incubation period, the unconjugated drug was separated by centrifugation at
10,000xg for 10 minutes and further washing particles twice with water. Additionally, the
conjugated particles were finally washed with methanol to remove any free DOX. The
DOX-conjugated particles were finally resuspended in water and stored at 4°C for further
analysis. Spheres of all size used for conjugation were also recovered from the film after
placing them in the hot oil bath as mentioned in section 3.3. This was done to expose the
carboxylic groups of spheres to the conditions like that of SR and LR.
The amount of drug conjugated was determined by measuring the absorbance at
485nm using TECAN plate reader (Tecan Group Ltd., Männedorf, Switzerland).
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Figure 5: Reaction scheme for conjugation of DOX to the carboxylic groups present on
the surface of the polystyrene particles using EDC-NHS chemistry.
3.6 Characterization of DOX Conjugation
3.6.1 DSC studies
Calorimetric studies of DOX, blank 10µm particles, physical mixture of DOX and
blank particles and DOX-conjugated particles were performed using DSC 6000 (PerkinElmer; Waltham, MA, USA) equipped with an intra-cooler accessory. About 1.5 mg of
sample was sealed in an aluminum pan, while a sealed empty pan was maintained as
reference. The samples were analyzed over the temperature range of 50°C to 300°C at a
heating rate of 10°C/min maintained under a nitrogen purge having flow rate of 50 mL/min.
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3.6.2 FT-IR
FT-IR analysis of the samples were performed using a Spectrum-100 (PerkinElmer, Inc.; Shelton, CT, USA) equipped with attenuated transmittance reflectance (ATR).
The spectra of DOX, blank particles, DOX-conjugated particles, and physical mixture of
DOX and blank particles were measured for comparison over 1000-4000 cm-1 range.
3.7 In-vitro Pulmonary Deposition Behavior
In-vitro deposition behavior reflects the aerodynamic behavior of the inhaled
particles and can be used to estimate the deposition pattern of particles in-vivo [62]. Invitro deposition behavior of DOX-conjugated particles were assessed using Next
Generation Impactor (NGI, MSP corporation, MN, USA) to predict the impact of particle
shape on aerodynamic properties using previously reported method [63,64]. Briefly, 2 mL
of DOX-conjugated particles at concentration of 450 µg/mL were nebulized using jet
nebulizer, PARI LC PLUS® nebulizer cup connected with Pari FAST-NEB compressor
system into pre-cooled impactor under vacuum maintained at 15 liters/minute for 4
minutes. The NGI was previously cooled at 4°C for 90 minutes to avoid heat-transfer which
otherwise may cause shrinkage of the nebulized droplets, thus causing impact on particles’
deposition behavior [65]. Following nebulization, particles deposited on each stage of NGI
were collected using a cell scrapper and were analyzed for drug amount present using
TECAN plate reader (Tecan Group Ltd., Männedorf, Switzerland), as described earlier.
Aerodynamic parameters such as fine particle fraction (% FPF) and mass median
aerodynamic diameter (MMAD) were calculated from the amount of drug deposited in
each stage. % FPF was determined as the fraction of emitted dose deposited in the NGI
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stages with <5.39 μm while MMAD (dae<5.39 μm) representing the aerodynamic particle
size distribution was calculated using log-probability analysis (n=3) [64].
All the further experiments were performed using10µm DOX-conjugated particles
(spheres, short rods, long rods).
3.8 In-vitro Release Studies
In-vitro release studies of all 10µm DOX-conjugated particles (spheres, short rods,
long rods) were performed using release method as previously reported with slight
modifications [66]. Briefly, 2 mg of DOX-conjugated particles were dispersed in 5 mL of
PBS pH 7.4 and acetate buffer pH 5.5. The samples were incubated at 37°C with
continuous shaking at 50 rpm. At predetermined intervals, the samples were centrifuged at
10,000×g for 10 minutes, and obtained supernatants were analyzed at 485 nm wavelength
using TECAN plate reader to determine the amount of DOX released.
3.9 Stability Studies
Stability studies of 10µm DOX-conjugated particles were performed by storing the
samples at two different conditions: 4°C (representing normal refrigerated storage) and
40°C/75%RH (accelerated stability storage) for a time interval of 15 days. Following the
storage period, the samples were analyzed in terms of particle size along with aspect ratio,
change in particle shape and amount of DOX-conjugated as µg of DOX/mg of particles.
3.10 Cellular Uptake Studies
The uptake of different shaped DOX-conjugated particles and free DOX was
evaluated on RAW 264.7 murine macrophages and H69AR human SCLC cells using
previously reported method [67]. Briefly, 1.0×104 cells/chamber were seeded on 823

chambered imaging coverslip (Eppendorf, Hauppauge, NY, USA) and were incubated
overnight at 37°C and 5% CO2. Cells were treated with DOX-conjugated particles or free
DOX (2.9 µg/mL) for 3 hours, following which they were washed twice with ice-cold PBS
(1X). The cells were then fixed using 4% paraformaldehyde for 10 mins and then again
washed with PBS (1X) to remove excess paraformaldehyde. The coverslip was separated
from chamber and was mounted on a clear glass microscopic slide using VECTASHEILD
hardset mountant containing DAPI (H1500, Vector laboratories). The cells were then
imaged using EVOS-FL fluorescence microscope (Thermo Fisher Scientific, Waltham,
MA, USA) at 20X magnification.
In addition to qualitative assessment, intracellular quantification of DOX was also
performed for understanding cellular uptake according to previously published method
[67]. Briefly, RAW 264.7 macrophages and H69AR cells were seeded at a density of 1.0
x 106 cells/well in 6-well plates and incubated overnight at 37°C and 5% CO2. The cells
were then treated with DOX and DOX-conjugated 10µm particles for 1 hr. and 3 hrs. After
the respective time interval, the treatment was aspirated, and cells were washed twice with
ice-cold PBS (1X). The cells were scrapped using cell scrapper and centrifuged to obtain a
cell pellet. The obtained pellet was washed twice using 1X PBS and was lysed using 100
µL DMSO. The lysed pellet was centrifuged again, and the obtained supernatant was
subjected to fluorometric analysis. The florescence intensity of DOX in each treatment
group was determined at excitation wavelength of 480 nm and emission wavelength of 590
nm using TECAN plate reader (Tecan Group Ltd., Männedorf, Switzerland) [68].
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3.11 Cytotoxicity Assessment
The cytotoxicity studies of free DOX and DOX-conjugated 10µm particles were
performed on RAW 264.7 macrophages, H69AR DOX- resistant SCLC cells and H9c2 rat
cardiomyoblasts using MTT assay. Briefly, RAW 264.7 and H69AR cells were seeded at
a density of 2.5×103 cells/well while H9c2 cells were seeded at 1.5×103 cells/well in tissue
culture treated 96 well plates (Eppendorf, Hauppauge, NY, USA), and were incubated
overnight at 37°C/5% CO2. Next morning, cells were treated with different DOXconjugated particles or free DOX; and were incubated for specific time points; RAW 264.7
macrophages (24 hrs. and 48 hrs.), H69AR cells (72 hrs.) and H9c2 cells (24 hrs.). After
respective treatment period, media was removed and MTT (1 mg/mL) was added followed
by 2 hrs. of incubation. Later, DMSO was added to each well after aspirating MTT solution.
Addition of DMSO helps to dissolve the formazan crystals formed during incubation of
cells with MTT solution. The plates were then shaken for 30 minutes on plate shaker and
the optical absorption was measured at 570 nm using TECAN plate reader (Tecan Group
Ltd., Männedorf, Switzerland). Cytotoxicity of particles was determined by comparing the
cell viability against the non-treated cells used as control groups. IC50 values were
determined by normalizing and transforming the data to log value using Graph Pad Prism
Software Version 6.0.
3.12 In-vitro Tumor Simulation Studies
In-vitro tumor simulation studies were performed to understand the therapeutic effect
of DOX and DOX-conjugated particles by mimicking the in-vivo tumorigenic conditions.
Briefly, H69AR small cell lung cancer (SCLC) cells were seeded at a density of 1.0×103
cells/well in a 96-well U bottom ultra-low attachment spheroid plate (Nuclon® Sphera,
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Thermo Fisher Scientific, Waltham, MA, USA) and incubated for 3 days at 37°C/5% CO2.
After incubation, cells were treatment in two different regimens: 1) single dose wherein
treatment was provided once only i.e., at the start of experiment and 2) multiple doses
where treatment provided every three days until the end of experiment (6 days). During the
treatment, half of the initial volume of media was replenished to avoid the possibility of
tumor aspiration or tumor damage. The tumors were characterized using several means as
outlined below to evaluate the anti-tumor activity of treatments.
a. Optical Imaging – Tumor spheroids were imaged at pre-determined intervals using
LMI-6000 inverted microscope (LAXCO, Bothell, WA, USA). The morphometric
parameters such as spheroid diameter and spheroid volume were calculated from the
images using Image J analysis software.
b. Cell Viability Assay – % Cell viability of tumor spheroids was determined using Cell
Titer-Glo™ 3D assay kit (Promega, Madison, WI, USA). Briefly, at the end of
experiment (Day 6), 50 µL of Cell Titer-Glo® 3D reagent was added in each well after
removing 150 µL of media (n=3 for each treatment group). After incubation of 30
minutes, the luminescence signal was measured using TECAN plate reader (Tecan
Group Ltd., Männedorf, Switzerland). The % cell viability was calculated for each
treatment group by comparing the viability against control.
c. Viable Cell Imaging – Viable cell imaging of the tumor spheroids was performed on
day 6 using calcein AM dye (Biotium, Fremont, CA, USA) which stains the viable cells
with green florescence. Briefly, 100 µL of florescent dye was added to each well after
carefully aspirating the treatment, followed by 30 minutes of incubation in dark.
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Labeled spheroid cells were imaged using EVOS FL florescence microscope (Thermo
Fisher Scientific, Waltham, MA, USA) at 4X magnification.
3.13 Evaluating Impact on Cardiotoxicity of DOX
3.13.1 Lactate Dehydrogenase (LDH) Assay
Cardioprotective effect of DOX-conjugated particles as against free DOX was
evaluated in H9c2 rat cardiomyoblasts using LDH assay. LDH-Glo™ cytotoxicity assay
(Promega, Wisconsin, MI, USA) kit was used to evaluate the toxicity of free DOX and
DOX-conjugated particles by measuring the LDH released from the cytosol due to loss of
membrane integrity of the cells. Briefly, H9C2 cells were plated in 24 well tissue culture
plates at 8.0×104 cells/well density and were incubated overnight at 37°C/5%CO2.
Following incubation, the cells were treated with 1.25 µM concentration of free DOX and
DOX-conjugated particles for 24 hours. Subsequently, the cells were treated with reagents
of LDH-Glo™ Cytotoxicity Assay (Promega, Wisconsin, MI, USA) as per the
manufacturer’s instructions. The luminescence of the treatment groups was measured using
TECAN plate reader.
3.13.2 Apoptosis Evaluation- Acridine Orange/Ethidium Bromide (AO/EB) Staining
DOX is known to induce apoptosis as one of the pathways to induce the
cardiotoxicity. Therefore, to evaluate the influence of DOX-conjugated particles in
providing protection against DOX induced apoptosis in H9C2 rat cardiomyoblasts,
acridine orange (AO) and ethidium bromide (EB) double florescent staining method as
reported previously was used [69]. Briefly, H9C2 cells were seeded at a density of 8.0×104
cells/well in a 24 well tissue culture plate and incubated overnight at 37°C/5% CO2
overnight. Post incubation, the cells were treated with free DOX and DOX-conjugated
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particles at a concentration of 1.25 µM for 24 hours. After the treatment period, cells were
washed twice with PBS pH 7.4 and stained using 200 µL of 1:1 AO:EB at concentration
of 100µg/mL each. The cells were incubated with dyes in dark for 30 minutes and imaged
at 20X magnification using EVOS-FL florescence microscope (Thermo Fisher Scientific,
Waltham, MA, USA)
3.15 Statistical Analysis
All the results are presented as mean±SD unless otherwise stated. Statistical
significance was determined using student’s t-test, one-way ANOVA and Tukey’s posthoc multiple comparison by GraphPad Prism 6.01 (San Jose, CA, USA). p<0.05 or less
was considered significant.
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4.0 Results and Discussion
4.1 Particle Fabrication and Morphology of Particles
Three different sizes of polystyrene particles were used to prepare elongated rodshaped (fiber like) particles. The rod-shaped particles were successfully fabricated using
one-dimensional film stretching as mentioned in the methods section. The particles were
imaged using SEM as seen in Figure 6, spherical particles over various sizes were
successfully transformed to rod shaped particles having varied aspect ratios. Aspect ratio
(AR) is defined as the ratio of the length of major axis of particles to the length of minor
axis of the particles. As seen from Table 1 and Figure 6, stretching of 0.5µm particles to
3 folds resulted into short rod (SR) shaped particles with major axis of 1.4 ± 0.1 µm and
minor axis 0.3 ± 0.0 µm resulting into AR of 4.08 ± 0.17. Upon further stretching the
particles to 6-fold, of 0.5µm particles produced particles long rods (LR) having major axis
length of 1.9±0.2 µm and minor axis length of 0.3 ± 0.0 µm possessing an AR value of
6.56 ± 0.60. As observed increase in stretching length from SR to LR resulted into increase
in AR value. Similarly, polystyrene particles of 6.0 µm equivalent diameter upon 3 folds
stretching resulted into SR with 9.1±0.9 µm (major axis length) and 1.7±0.3 µm (minor
axis length) causing an AR value of 5.4±0.8. Further, LR of 6.0 µm equivalent diameter
displayed 13.7±1.6 µm (major axis length) and 1.5±0.4 (minor axis length) resulting into
9.14 ± 1.42 AR value (Table 1 and Figure 6).
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Figure 6: Representative scanning electron microscopy (SEM) micrographs of particles
obtained by stretching microparticles of various sizes. Scale bar= 10µm
Table 1: Calculated particle size of stretched particles using Image J software. Data
represents mean±SD for 3 individual images with n=30 for each sample.
Sample

Major axis
length (µm)

Minor axis
length (µm)

Aspect Ratio
(Major axis/Minor axis)

0.5µm-SR

1.4 ± 0.1

0.3 ± 0.0

4.1 ± 0.2

0.5µm-LR

1.9 ± 0.2

0.3 ± 0.0

6.6 ± 0.6

6.0µm-SR

9.1 ± 0.9

1.7 ± 0.3

5.4 ± 0.8

6.0µm-LR

13.7 ± 1.6

1.5 ± 0.4

9.1 ± 1.4

10µm-SR

22.1 ± 3.3

7.1 ± 0.9

3.3 ± 0.5

10µm-LR

32.2 ± 3.2

5.6 ± 0.9

5.8 ± 1.1
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Stretching of 10.0 µm particles to 3 folds resulted into fabrication of SR particles
with 22.1 ± 3.3 µm major axis length and 7.1 ± 0.9 µm of minor axis length accounting for
AR value of 3.3 ± 0.5. Similarly, stretching to 6 folds formed LR particles with 32.2 ± 3.2
µm (major axis length) and 5.6 ± 0.9 µm (minor axis length) resulting into 5.8 ± 1.1 AR
value as can be seen in Table 1 and Figure 6. Interestingly it was observed that AR values
of both SR and LR particles stretched from10.0 µm equivalent diameter size was found to
be less than their respective counterparts of 6.0 µm and 0.5 µm equivalent diameter size
particles. This reduction in the AR value of 6.0 and 10.0 µm equivalent diameter particles
as against 0.5 µm can be attributed to the crosslinking of the polystyrene particle; as these
large sized particles were reported to be crosslinked with divinylbenzene (Manufacturer
protocol, Polysciences Inc.). Polymer crosslinking is known to restrict the rotational
motion of the polymer molecules resulting into increase in the glass transition temperature
of polymer which increases the rigidity of the polymer [70]. The increased rigidity of the
polymer hampers the flexibility of the particle to be stretched and thus resulting into lower
AR values. These results infer that particle of various size can be successfully transitioned
from spherical to rod shape by employing the stretching method.
4.2 Conjugation of Drug with Particles
DOX was chosen as the model drug for conjugation with the particles due to the 2
major reasons : 1) widely explored conjugation chemistry and 2) inherent florescence
which can be used in the in-vitro studies. The fabricated particles were conjugated with
DOX using EDC-NHS chemistry and the amount of DOX-conjugated was analyzed by
measuring UV absorbance. As seen in Figure 7, the amount of DOX-conjugated to
particles of 0.5 µm size was found to be 454.6 ± 2.0 µg of DOX/mg of particles (Sph),
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469.1 ± 5.3 µg of DOX/mg of particles (SR) and 425.8 ± 5.5 µg of DOX/mg of particles
(LR). Upon increasing the particle size from 0.5 to 6.0 µm, the amount of DOXconjugated/mg of particles remained almost same as in Figure 7.

Figure 7: Characterization of DOX conjugation to various 10µm particles. (A) amount of
DOX-conjugated to various particles expressed as µg of DOX/mg of particles. Data is
represented as mean±SD for n=3 experiments.
6.0µm-Sph showed 400.1 ± 2.6 µg of DOX/mg of particles while stretched particles
displayed 386.2 ± 6.5 µg of DOX/mg of particles (6.0µm-SR) and 367.7 ± 1.7 µg of
DOX/mg of particles (6.0µm-LR). Further increasing the particle size to 10µm,
conjugation of DOX was found to be unaffected with 10µm-Sph illustrating 425.5 ± 3.3
µg of DOX/mg of particles. The stretched particles 10µm-SR displayed 406.1 ± 1.2 µg of
DOX/mg of particles while 10µm-LR demonstrated 399.0 ± 1.9 µg of DOX/mg of particles
being conjugated (Figure 7). The amount of DOX-conjugated to carboxylic acid groups
functionalized on particles across various size and shape almost remained similar. This
indicates that carboxylic acid functionalized on the surface of polystyrene particles remain
unaffected by the stretching owing to its hydrophilic nature and thus are believed to be
readily available for conjugation. The amount of carboxylic acid groups available for
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conjugation on particles is attributed to be dependent on the total particle volume indicating
that increase in size of particle causes increase in amount of carboxylic acid groups [71].
Therefore, to equalize the amount of carboxylic acid available for conjugation amongst the
particles various size and shapes, we have used a constant total mass of particles for
conjugation reaction. This values of µg of DOX/mg of particles were found to be almost
equivalent as seen in Figure 7.
4.3 Characterization of DOX Conjugation
4.3.1 DSC Studies
Calorimetric studies was performed to evaluate the conjugation of DOX with the
particles. Figure 8A represents the thermogram of the analyzed samples, wherein DOX
shows a sharp endothermic peak at 206.2°C representing the melting of DOX as also
reported in literature [72,73]. Thermogram of blank particles displays a small endothermic
peak at 103.2°C representing the glass transition (Tg) temperature of polystyrene [74,75].
Thermal study result of physical mixture of DOX and blank particles demonstrate first
endothermic peak at 105.3°C due to Tg of blank particles and second at 198.4°C
representing melting point of DOX as in Figure 8A. In case of all the DOX-conjugated
particles, the characteristic peak of DOX was found to be absent, indicating that pure DOX
was not present in the conjugated particles and was removed during washing steps
suggesting that DOX present in the formulation is bound to the particles. These results also
indicate that DOX was bound strongly to the particles resulting into formation of a stable
bond [73].
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(A)

(B)

Figure 8: Characterization of DOX conjugation to various 10µm particles. (A)
Thermograms of samples analyzed using differential scanning calorimetry (DSC). (B)
Spectra of samples analyzed using FT-IR also a representative magnified image of spectra
is shown for all the samples.
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4.3.2 FT-IR studies
Thermal spectra of analyzed samples are displayed in Figure 8B wherein DOX
displays several characteristic peaks at 3315 cm-1 (-N-H2 stretching), 2916 and 2898 cm-1
(-C-H stretching of phenol rings), 1730 cm-1 (-C=O ketone stretching and C-H2 bending),
1617 cm-1 (-CO-H bending), 1580 cm-1 (-C=O quinone stretching), 1525 cm-1 (out of pane
vibration of -N-H2) and 881 cm-1 (-C-N bending) [76–78]. Polystyrene particles
demonstrated peaks at 3106 cm-1, 3079 cm-1 and 3026 cm-1 (C-H stretching of aromatic
rings and -O-H stretching of carboxylic acid), 2930 cm-1 and 2849 cm-1 (-CH2- stretching),
1620 cm-1 ,1511 cm-1 and 1470 cm-1 (C=C stretching of aromatic rings) [79,80] (Figure
8B). Analysis of all the three DOX-conjugated particles (10µm-Sph, 10µm-SR and 10µmLR) demonstrated majority of characteristic peaks of DOX at ~ 3315 cm-1, 2916 cm-1, 1730
cm-1 and 1580 cm-1 indicating the presence of DOX in the conjugated particles. However,
as seen in Figure 8B conjugation of DOX to polystyrene resulted into substitution of 1525
cm-1 (out of pane vibration of -N-H2) of DOX with peak at 1509 cm-1 (10µm-Sph), 1502
cm-1 (10µm-SR) representing amide II vibrations of -N-H and -C-N stretching, indicates
the involvement of -NH2 group to form the -CONH bond [81,82]. These FT-IR results
indicates successful conjugation of DOX to the polystyrene particles via amide bond
linkage between the carboxylic acid (-COOH) groups of polystyrene particles and amine
(-NH2) group of DOX
4.4 In-vitro Pulmonary Deposition Behavior
The aerodynamic behavior of the fabricated particles were assessed using NGI
measured in terms of MMAD and % FPF. The data of the impact of particle shape and size
on in-vitro pulmonary deposition is shown in Table 2.
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Table 2: Aerosolization properties of various microparticles calculated in terms of MMAD
and % FPF. Data is represented as mean±SD for n=3 experiments. *p<0.05, ** p<0.01,
**** p<0.001 and **** p<0.0001.
Sample

MMAD

% FPF

0.5µm-Sph

4.5 ± 0.3

77.2 ± 5.0

0.5µm-SR

4.2 ± 0.5

74.2 ± 0.7

0.5µm-LR

4.4 ± 0.4

79.5 ± 5.7

6.0µm-Sph

5.6 ± 0.1

61.7 ± 2.1

6.0µm-SR

4.3 ± 0.2**

76.5 ± 4.9*

6.0µm-LR

4.7 ± 0.1**

76.2 ± 1.1*

10µm-Sph

8.2 ± 0.8

44.7 ± 5.7

10µm-SR

4.2 ± 0.6****

89.5 ± 9.6***

10µm-LR

3.4 ± 0.1****

95.5 ± 0.6****

Aerodynamic parameters of 0.5 µm particles assessed using NGI are shown in
Table 2. All the three particles; 0.5µm-Sph, 0.5µm-SR and 0.5µm-LR demonstrated
MMAD ~4.5 along with no significant difference observed in % FPF value reported to be
>75%. Increase in the particle size from 0.5 µm to 6.0 µm resulted into increase in the
MMAD of 5.6 ± 0.1 (for 6.0µm-Sph) along with % FPF value of 61.7 ± 2.1 indicating
maximum deposition occurring the proximal region of the respiratory tract. However,
transition of particle shape from spheres to rod resulted into significant (p<0.01) reduction
in MMAD value as 4.3 ± 0.2 for 6.0µm-SR and 4.7 ± 0.1 as observed for 6.0µm-LR (Table
2). On the other hand, % FPF values for 6.0µm rod shaped particles were found to be
significantly (p<0.05) increased as against the spherical particles as seen in Table 2.
6.0µm-SR resulted into 76.5 ± 4.9 % FPF value and 6.0µm-LR displayed 76.2 ± 1.1 % FPF
36

value. Similarly, MMAD value for 10µm-Sph as reported in Table 2 indicated a high
MMAD value of 8.19±0.8 µm while the stretched particles demonstrated a significantly
(p<0.0001) lower MMAD values of 4.2 ± 0.6 µm for 10µm-SR particles and 3.4 ± 0.1 µm
for 10µm-LR particles, respectively. Upon comparing the % FPF value (Table 2), 10µmSph displayed ~45% while rod-shaped particles demonstrated significant (p<0.0001)
increase in % FPF with ~90% for 10µm-SR and ~95% for 10µm-LR particles. This
increase in % FPF indicates that most of the emitted dose will be deposited in the respirable
region of the lungs which comprises of the bronchi-alveolar region.
The deposition of 10µm DOX-conjugated particles on various stages of NGI are
represented in Figure 9A. As can been seen from the Figure 9A, for 10µm-Sph particles,
the deposition was seen mostly in stage 1 (~4 µg), stage 2 (~ 6 µg), stage 3 (~5 µg) and
stage 4 (~3 µg) while ≤ 1 µg DOX deposition was observed from stage 5 to stage 8. This
indicated that deposition of 10µm-Sph predominantly occurred above the bronchi-alveolar
regions. The stretched particles: 10µm-SR and 10µm-LR on the other hand showed
minimal deposition at stage 1 and 2 (≤ 1 µg). The deposition of stretched particles, both
SR and LR increased dramatically stage 3 onwards. Maximum deposition of particle for
stretched particles was observed in stage 5 wherein ~ 22 µg of DOX was quantified for
10µm-SR and ~28 µg DOX for 10µm-LR particles. At stage 6, the deposition of DOX
decreased to ~16 µg for 10µm-SR while the reduction in deposition behavior of 10µm-LR
particles was mild with ~25 µg DOX observed for 10µm-LR. The deposition of 10µm-LR
particles as could be seen in Figure 9A continued until stage-8 with ~5 µg DOX observed
while the 10µm-SR particles displayed ~0.5 µg DOX.
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(B)

Figure 9: (A) Aerodynamic distribution pattern of various 10µm particles at different
stages of Next Generation Cascade Impactor (NGI) expressed as DOX Deposition (µg) at
each stage. (B) % Cumulative deposition plotted against effective cut-off diameter
(microns) to determine deposition impact due to difference in particle shape of 10µm
particle. Data represents mean ± SD (n=3). ** p<0.01
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Since majority of deposition for 10µm-SR and 10µm-LR stretched particles beyond
stage 3 (representing bronchi-alveolar region), it can be confirmed that change in the shape
of the particles enhance the deposition of particles in the deeper lungs. The % cumulative
deposition plot as in Figure 9B indicated that 50% of the cumulative dose for 10µm-Sph
deposited at the effective cut-off aerodynamic diameter of 5.57 µm. The stretched particles
demonstrated a significantly (p<0.0001) lower effective cut-off aerodynamic diameter for
50% cumulative deposition: 2.53 µm for 10µm-SR particles and 2.26 µm for 10µm-LR
particles (Figure 9B). These results support the fact that rod shaped particles (stretched
particles) improve the deposition behavior of the particles as against the spherical particles
resulting into maximum deposition at lower aerodynamic diameter. This can be attributed
to the better propulsion of rod-shape particles down the respiratory tract after aligning
themselves with the air flow [83]. Several computational fluid dynamics simulation models
have predicted the deposition of fiber (elongated rod shaped; AR>3) vs sphere particles in
the lungs, wherein elongated particles streamlines themselves to the air flow and therefore
tend to deposit in the peripheral airways [83–85]. Particle shape is also reported to
influence the mechanism of particle deposition in lungs; wherein the spherical particles
tend to deposit predominantly by inertial impaction (for MMAD>5 µm), gravitational
sedimentation (for MMAD 1 to 5 µm) or diffusion (for MMAD ≤0.5 µm) [34,37,86]. While
the rod-shaped particle on the other hand deposit by interception, wherein the fiber like
particles comes in close contact to the surface such that it touches the surface which would
have been missed by the center of the mass [36]. Increase in the length of particles results
into increase in the deposition of particles via interception which allows the particles to
streamline with the airflow and travel to the distal airways in the alveolar region [87]. This
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justifies the improved aerodynamic behavior of rod-shaped particles against spheres and
amongst the rod-shaped particles, LR better than SR. Therefore, the results of in-vitro
pulmonary deposition behavior have been successful in supporting the hypothesis that
changing the shape of spherical particles to rod-shape results into deeper lung deposition
of particles.
4.5 In-vitro Release of DOX-conjugated Particles
The release of DOX from conjugated polystyrene particles was analyzed in buffers
at pH 7.4 mimicking physiological conditions and pH 5.5 representing lysosomal vesicles
and microenvironment of cancer cells [88,89]. As seen in Figure 10, no burst release of
DOX was observed in the in-vitro release study. The release of DOX was observed to be
pH dependent which indicated that release of DOX was faster at lower pH value of 5.5 as
compared to higher pH 7.4. DOX-conjugated particles upon incubation at pH 5.5 released
about 45.2 ± 2.8 % of DOX from 10µm-Sph particles, 43.8 ± 1.3 % DOX from 10µm-SR
particles and 45.7 ± 1.3% DOX from 10µm-LR particles after 5 days (Figure 10). While
significantly (p<0.0001) small amount of DOX was found to be released at physiological
pH 7.4 due to slower hydrolysis of the amide bond [81]. The % drug released after 5 days
incubation of 10µm-Sph particles was 18.9 ± 2.3% while 10µm-SR particles displayed
18.7 ± 3.0% and 10µm-LR particles showed 18.7 ± 3.7% cumulative release of drug
(Figure 10). On the other hand, increased release of DOX from the particles at acidic pH
is known to be mediated cleavage of the amide bond due to acid hydrolysis resulting into
subsequent release of DOX in the media [81,88]. These results are in accordance to other
studies wherein slower release of DOX at pH 7.4 indicated enhanced stability of amide
conjugated DOX particles and its slower hydrolysis kinetics at normal physiological
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conditions [81,89–91]. In addition, the slower release of DOX at physiological pH supports
the use of these conjugated particles as effective delivery carrier due to reduced loss of
DOX while reaching the site of action resulting into low off-target side effects and
increased tumor accumulation [92,93].

Figure 10: In-vitro drug release profile of DOX from various 10µm particles; 10µm-Sph,
10µm-SR and 10µm-LR evaluated at pH 7.4 and pH 5.5. Data represents mean ± SD (n=3).
4.6 Stability Studies
Stability of 10µm DOX-conjugated particles were tested after storing for 15 days
at two different conditions: 1) storage conditions represented by 4°C and 2) accelerated
stability conditions represented by 40°C and 75% relative humidity (RH). The stability was
assessed in terms of particle shape, particle size and the amount of drug conjugated. Figure
11A represents the SEM images of the particles, wherein there was no change observed in
the shape of the particles when stored at accelerated conditions as against normal storage
conditions. This can be attributed to the high glass transition temperature (110°C) of the
polystyrene particles remaining unaltered at the accelerated conditions (40°C/75% RH)
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and thereby maintain the same shape. Furthermore, the size of the stretched particles were
measured using ImageJ software to evaluate if any existed in the particles. As seen in
Figure 11B, the major axis of the 10µm-SR particles at 4°C was found to be 25.2 ± 1.2
µm (vs. 24.6 ± 1.9 µm at 40°C/75%RH) and minor axis of 24.6 ± 1.9 µm (vs. 7.9 ± 0.9
µm for 40°C/75%RH). The aspect ratio of particles also showed non-significant difference
with 3.5 ± 0.4 at normal conditions vs. 5.9 ± 0.9 at accelerated condition. Similarly, 10µmLR particles also displayed non-significant changes in particle size parameters as in Figure
11B. The length of major axis at 4°C was found to be 36.2 ± 2.0 µm while at 40°C/75%RH
it was reported to be 36.7 ± 2.5 µm. The minor axis of 10µm-LR particles at normal
conditions was found to be 6.1 ± 0.9 µm at vs. 5.9 ± 0.9 µm at accelerated conditions. Upon
analyzing the aspect ratio values, no significant differences were observed between 4°C
with 6.4 ± 1.0 compared to 6.3 ± 1.2 at 40°C/75%RH (Figure 11B).
Furthermore, the amount of conjugated to the particles was analyzed at the end of
the stability period. As seen in Figure 11C, 10µm-Sph displayed 426 ± 10µg of DOX/mg
of particles at 4°C as against 421 ± 9 µg of DOX/mg of particles at 40°C/75%RH. 10µmSR particle demonstrated ~430 mg of µg of DOX/mg of particles at both the stability
conditions. Similarly, 10µm-LR particle displayed non-significant changes with ~460 µg
of DOX/mg of particles at both the stability conditions. This non-significant difference in
the amount of conjugated drug present at both the stability conditions can be attributed to
the stable amide bond conjugation between DOX and the carboxylic acid of the polystyrene
particles which remains unaffected at the increased temperature [94]. These results indicate
the superior stability of DOX-conjugated particles at the accelerated conditions.

42

(A)

(C)

Figure 11: Stability of various 10µm particles evaluated at two different conditions; 4°C
and 40°C/75%RH, after 15 days storage evaluated for changes in morphology, particle
size, and amount of drug conjugated. (A) Stability evaluated in terms of morphological
changes of particles represented by respective SEM micrographs. (B) Stability evaluated
in terms of major axis length, minor axis length and aspect ratio of particles and (C)
Stability evaluated in terms of µg of DOX/mg of particles present at the end of 15 days.
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4.7 Investigating Escape of Particles by Macrophages
4.7.1 Cellular Uptake
The cellular uptake of DOX-conjugated spherical and stretched particles was
analyzed using fluorescent microscope after incubation of particles for 3 hr. As seen in
Figure 12A, DOX demonstrated enhanced internalization with DOX florescence (Red)
being overlapped over the cellular nuclei (DAPI- blue fluorescence). This indicates that
free DOX was readily localized in the cell nucleus of RAW 264.7 cells. For 10µm-Sph
particles, it can be observed that DOX was conjugated to the spherical particles and
distributed in the cytoplasm surrounding the nuclei of RAW 264.7 cells. The stretched
particles 10µm-SR displayed presence of some DOX particles in the cytoplasm of the cells,
however the florescence intensity of DOX was comparatively less than the spherical
particles indicating reduced cellular uptake of the 10µm-SR stretched particles (Figure
12A). For 10µm-LR particles as in Figure 12A, there was minimal DOX florescence
observed in the cytoplasm or nuclei of the cells suggesting impact of particle shape on the
cellular uptake by the macrophage cells. Based on these results, it can be inferred that
change in the shape of the particles may influence the uptake of the particles by
macrophages.
The intracellular uptake of free DOX and DOX-conjugated particles was analyzed
by quantifying the florescence of DOX. As demonstrated in Figure 12B, free DOX
displayed the highest florescence intensity at both the incubation time; 1 hr. and 3 hrs.
Furthermore, free DOX demonstrated significantly (p<0.001) stronger florescence
intensity than 10µm particles (spherical and stretched) at both 1 hr. and 3 hrs. incubation
time.
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Figure 12: In-vitro cellular uptake studies of various 10µm particles. (A) Florescent
images of DOX, 10µm-Sph, 10µm-SR and 10µm-LR in RAW 264.7 macrophages after 3
hrs. incubation. The inset images represents magnified image of the outside image.
Representative images from n = 3 experiments. Scale bar = 100 µm (B) Quantitative
determination of intracellular DOX after 1 hr. and 3 hrs. incubation in RAW 264.7 cells
represented as florescence intensity. Data represent mean ± SD (n=3). *p<0.05, ** p<0.01,
**** p<0.001 and **** p<0.0001.
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Amongst, 10um particles Sph demonstrated significantly higher florescence
intensity after 1 hr. incubation ~1.7-folds (p<0.05) and ~2.4 folds (p<0.01) than 10µm-SR
particles and 10µm-LR particles, respectively. However, at 1 hr. incubation there was no
significant difference observed between the fluorescence intensity of 10µm-SR particles
and 10µm-LR particles. The florescence intensity of 10µm-sphere particles after 3 hrs.
incubation displayed ~1.4 folds (p<0.01) increased florescence intensity as against 10µmSR particles while ~2.4 folds (p<0.001) increase as compared to 10µm-LR particles as in
Figure 12B. Additionally, 10µm-SR particles displayed significantly (p<0.01) higher
fluorescence of ~1.5 folds when compared to 10µm-LR particles. The results of this study
are also corroborated by the fluorescence imaging results depicting the escape of 10µmLR particles from macrophage uptake.
The enhanced internalization of free DOX in the macrophages can be attributed to
the rapid passive diffusion mechanism of DOX [95,96]. Whereas internalization of DOXconjugated 10µm particles (both spheres and stretched particles) may undergo energy
dependent uptake pathway such as phagocytosis and therefore display comparatively
reduced uptake as against DOX [97]. The results further demonstrate that change in the
shape of the particle from sphere to rod results into reduced uptake by macrophages. This
in accordance to several studies reporting that macrophage uptake is highly influenced by
the shape of particles wherein spherical particles are readily internalized as compared to
non-spherical shape [61,98,99]. This effect is further escalated for particles with higher
aspect ratio, wherein macrophages are not able to completely engulf such particles due to
incomplete formation of actin pseudopods around the particles resulting into reduced

46

cellular internalization [99,100]. Therefore, particles with higher aspect ratio have higher
possibility to escape the macrophage uptake which in our case is 10µm-LR particles.
4.7.2 Cytotoxicity Assessment on Macrophages
Cytotoxicity of free DOX and DOX-conjugated 10µm particles (Sph, SR, and LR)
was assessed on RAW 264.7 cells using MTT assay after 24 hrs. and 48 hrs. incubation
time. Figure 13A represents the % cell viability of RAW 264.7 cells after 24 hrs. treatment
wherein free DOX demonstrated highest cytotoxicity of macrophages amidst all the
treatment group with an IC50 value of 1.06 ± 0.1µM. The DOX-conjugated spherical
particles at 5µM concentration displayed ~70% cell viability while stretched particles SR
and LR displayed ~75% cell viability (Table 3). Further, DOX displayed time dependent
cytotoxicity on macrophages as can be observed in Figure 13B and Table 3 with IC50
value of 0.08 ± 0.03 µM. The treatment with DOX-conjugated 10µm-Sph displayed ~28
folds increase in IC50 value; 2.8 ± 0.8 µM as compared to DOX. The stretched 10µm-SR
particles displayed ~31 folds increase in IC50 value as compared to free DOX and ~1.1
folds increase against 10µm-Sph with an IC50 of 3.1 ± 0.1 µM. Treatment with 10µm-LR
particles resulted into significant (p<0.01) ~71 folds increase in IC50 against DOX with
IC50 of 7.5 ± 3.1 µM. Additionally, 10µm-LR particles displayed ~2.7 folds (p<0.05)
increase in IC50 as against 10µm-Sph and ~2.5 folds (p<0.05) increase against10µm-SR
particles (Figure 13B and Table 3). Based on the cytotoxicity results, treatment group can
be in the ranked in the following order for displaying cytotoxicity against RAW 264.7
macrophages: DOX>10µm-Sph>10µm-SR>10µm-LR. These outcomes are in accordance
the results of cellular uptake wherein DOX is demonstrated to be readily internalized by
macrophages via diffusion causing higher cytotoxicity.
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Figure 13: In-vitro cytotoxicity studies of various 10µm particles in RAW 264.4 cells
determined using MTT assay. (A) Cytotoxic potential of DOX conjugated DOXconjugated 10µm particles evaluated after 24 hrs. incubation (B) Cytotoxic potential of
DOX conjugated DOX-conjugated 10µm particles was evaluated after 48 hrs. incubation
(C) Blank particle cytotoxicity evaluated in RAW 264.7 cells after 24 hrs. incubation and
(D) Blank particle cytotoxicity evaluated in RAW 264.7 cells after 48 hrs. incubation.
(Data represent mean ± SD of 3 individual experiments with n=6 for each experiment).
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Amongst DOX-conjugated 10µm particles, stretched particle with highest aspect
ratio i.e., 10µm-LR particles escape the cellular uptake by macrophages and thereby
demonstrate significantly reduced cytotoxicity. The cytotoxicity of blank particles was also
assessed in Raw 264.7 cells after 24 hrs. and 48 hrs. incubation. As seen in Figure 13C,
after 24 hrs. of incubation all the blank particles demonstrated >85% cell viability. Similar
results were observed after 48 hrs. incubation of particles as in Figure 13D, wherein all
the particles displayed >80% cell viability against the macrophages indicating that the
particles were safe against the RAW 264.7 cells. These findings indicate that the
cytotoxicity of DOX-conjugated particles observed in macrophages is because of DOX
from the conjugated particles internalized by the cells and not due to the polystyrene
particles.
Table 3: IC50 values of different treatment groups in RAW 264.7 cells calculated from
experimental cytotoxicity data obtained after 48 hrs. incubation
Treatment Group

IC50 value (µM)

DOX

0.1 ± 0.0

10µm-Sph

2.8 ± 0.8

10µm-SR

3.1 ± 0.1

10µm-LR

7.5 ± 3.1

4.8 Evaluating Impact of Particle Shape Against Small Cell Lung Cancer (SCLC)
SCLC was chosen as a model disease to predict the impact of particle shape of
delivery carriers on the effectiveness of treatment. Lung cancer is known to be second most
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common cancer accounting for ~2 million death worldwide [101]. SCLC represents about
13% to 15% of the total lung cancer cases and is referred as the most aggressive form of
lung cancer [102]. In this project, multidrug (including DOX) resistant H69AR SCLC cells
were used to evaluate the efficacy of treatment against the tumorigenic property of SCLC
cells. The reason to use DOX resistant H69AR cell line was the extremely low IC50 of DOX
~0.7 µM in the non-drug resistant variant H69 [103,104]. We believed that treatment of
cells with DOX-conjugated particles at such low concentration may not will lead to
extremely small number of particles being exposed to cells which may not truly reflect the
effectiveness of particle shape on treatment against tumorigenic activity of cells
4.8.1 Cellular Uptake
The uptake of DOX-conjugated particles was assessed in DOX resistant SCLC cells
after incubation for 3 hours using florescence microscope. As seen in Figure 14A, DOX
(red florescence) was seen to be readily up taken by the cells and was localized in the
nucleus (blue florescence). When DOX-conjugated particles were incubated with the cells,
the florescence was observed in the cytoplasm of the cells unlike the free DOX which was
localized in nucleus. The stretched particles displayed higher DOX florescence in the
cytoplasm around the cells as compared to the 10µm sphere particles. Amongst the
stretched particles, 10µm-LR particles displayed greater florescence than 10µm-SR
particles (Figure 14A).

50

(A)

(B)

Figure 14: Cellular uptake studies of DOX-conjugated 10µm particles in H69AR cells
after 3 hrs. incubation. Florescent images of DOX, 10µm-Sph, 10µm-SR and 10µm-LR in
H69AR cells. Representative images from n = 3 experiments. Scale bar = 100 µm (B)
Quantitative determination of intracellular DOX after 3 hrs. incubation in H69AR cells
represented as florescence intensity. Data represent mean ± SD (n=3). *p<0.05 and **
p<0.01.
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In addition to florescence imaging, we have also evaluated cellular uptake by
quantifying the florescence of DOX internalized by the cells after incubating for 3 hours.
Figure 14B demonstrates the results of cellular uptake determined by measuring the
florescence quantification, wherein free DOX showed highest florescence intensity
amongst all the treatment group. The florescence intensity of DOX was found to be
significantly (p<0.01) higher than 10µm-Sph particles and 10µm-SR particles. DOXconjugated particles showed shape dependent impact on the cellular uptake with 10µmsphere particles showing the minimal florescence intensity. The increase in aspect ratio led
to increase in the florescence intensity with 10µm-SR particles showing ~1.2 folds increase
as compared to 10µm-sphere particles. Similarly, 10µm-LR particles showed ~1.4 folds
significant (p<0.05) increase in florescence intensity compared to spherical particles
(Figure 14B).
These results are in accordance with the cellular uptake florescence imaging data
indicating shape dependent effect of particles on uptake by SCLC cells wherein elongated
particles are readily internalized compared to spherical particles. The increased uptake of
DOX in the obtained results can be attributed to the gradient mediated passive diffusion
while the DOX-conjugated particles undergo phagocytosis by the SCLC cells. These
findings are in accordance to the previously published studies where microparticles with
higher AR values are internalized faster by cancer cells [105,106].. Increase in the aspect
ratio of conjugated particles resulted in increased uptake by cancer cells [105,107]. This
can be because of increased fluidity of cancer cells’ plasma membrane due to varied lipid
metabolism resulting into improved uptake of the stretched particles (elongated with sharp
ends) as against spherical particles unlike what was observed in the normal cells like
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macrophages [107–109]. These results confirmed that increase in aspect ratio of particles
results into improved uptake of particles by SCLC cells.
4.8.2 Cytotoxicity assessment in SCLC cells
The cytotoxicity of free DOX and DOX-conjugated particles was evaluated by
MTT assay after incubating H69AR cells for 72 hours over concentration range of 0.2 to
30 µM. Results as shown in Figure 15A indicate that free DOX has the highest cytotoxicity
over the concentration range tested with an IC50 value of 8.3 ± 2.3 µM (Figure 15B).
Treatment with 10µm-Sph showed a significant (p<0.001) ~2.6 folds reduction in the
cytotoxicity against H69AR cells with an increased IC50 value of 21.6 ± 1.8 µM as
compared to free DOX. Shape dependent effect was observed in the cytotoxicity of DOXconjugated particles, wherein rod-shaped particles demonstrated better cytotoxicity against
SCLC cells as compared to spherical particles. 10µm-SR particles showed improved
cytotoxicity with reduced IC50 value of 18.1 ± 2.4 µM as against 10µm-Sph (Figure 15A
and 15B). While treatment with 10µm-LR particles showed significant (p<0.05)1.4 folds
reduction in IC50 value with 15.8 ± 2.5 µM as compared to 10µm-Sph particles, indicating
superior cytotoxic effect against H69AR cells. These results are also supported by the
cellular uptake results which infer that change in the shape of particles resulting into
increased aspect ratio imparts improved cytotoxicity against SCLC cells. Blank particles
cytotoxicity was also evaluated on H69AR cells after incubation for 72 hours. As can be
seen in Figure 15C, all the three particles demonstrated >85% cell viability over the
concentration range of 0.2 µM to 30 µM concentration. These results confirm that the blank
particle are safe against H69AR cells and the cytotoxic effects observed is due to the DOX
conjugated to the particles which was cleaved upon phagocytosis in the SCLC cells.
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Figure 15: Cytotoxicity studies of various treatment groups after 72 hrs. incubation in
H69AR cells. (A) Cytotoxic potential of DOX, and DOX-conjugated 10µm-Sph, 10µmSR and 10µm-LR expressed as % cell viability. (B) IC50 values of DOX DOX and DOX
conjugated particles calculated from the experimental cytotoxicity data (C) Cytotoxic
potential of blank 10µm-Sph, 10µm-SR and 10µm-LR particles expressed as % cell
viability. (Data represent mean ± SD of 3 individual experiments with n=6 for each
experiment).
54

4.8.3 In-vitro Tumor Simulation Studies
The monolayer cell culture studies (2D) does provide valuable information about the
behavior of particles with cells; however, it does not truly reflect the in-vivo conditions.
Therefore, to better assess the influence of particle shape in tumor conditions we performed
in-vitro tumor simulation studies also known as 3D spheroid cell culture studies which
simulates physiological tumorigenic conditions and provide relevant understanding about
the therapeutic behavior of treatment as compared to the traditional monolayer studies
[110,111]. 3D spheroid tumor models have been extensively explored in high throughput
screening of lead compounds, evaluating the drug safety and efficacy profile, assessing the
development of drug resistance and anti-tumorigenic activity of the delivery systems [112–
114]. In this study, we have utilized in-vitro tumor simulation studies to evaluate the
particle shape dependence on the anti-tumor activity of DOX-conjugated particles against
H69AR SCLC cells. The study was performed at two different doses: 1) single dose study
involves treatment to the cells only once at the start of experiments and 2) multiple doseinvolves treatment at every 72 hours until the end of study. The anti-tumor efficacy of the
treatment against the SCLC cells was measured in terms of spheroid volume, % cell
viability in spheroids and imaging the live cells present in the spheroids using live-dead
cell assay.
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Figure 16: Effect of single dose treatment on tumorigenic activity of H69AR cells grown
as 3D spheroids simulating in-vivo tumor conditions. (A) Representative images of
spheroids demonstrating suppression in tumor growth at days 0, 3 and 6. Scale bar = 200
µm (B) Quantitative representation of anti-tumor activity of treatment expressed as
spheroid volume (mm3) versus time (days) for single dose treatment. Data represent
mean±SEM (n = 6).
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A) In-vitro Tumor Simulation Studies- Single Dose
Figure 16A represents the tumor images of single dose treatment groups captured at
different time intervals. As can be seen from the figure, control (untreated) group displayed
uncontrolled tumor growth resulting into 40.7 ± 2.9 mm3 volume of the spheroids at Day
6 (Figure 16B). Treatment with DOX and DOX-conjugated particles resulted into
significant inhibition of tumor growth. DOX treatment resulted into inhibition in tumor
growth along with loss of tumor integrity at Day 6 (Figure 16A) and a significant
(p<0.001) 4.6 folds reduction in spheroid volume (8.8 ± 0.4 mm3) as compared to control
(Figure 16B). On the other hand, DOX-conjugated particles showed shape dependence
anti-tumor effect against the H69AR spheroids wherein 10µm-Sph showed significant
(p<0.001) 1.6 folds reduction in tumor growth as compared to control with tumor volume
of 24.9 ± 0.5 mm3 on day 6 and no influence on tumor integrity (Figure 16A and 16B).
While rod-shaped particles demonstrated superior tumor growth inhibition of SCLC
spheroids as against spherical particles. 10µm-SR particles showed ~3.5 folds significant
inhibition (p<0.001) of spheroid volume (7.2 ± 0.7 mm3) and loss of tumor integrity at day
6 when compared to 10µm-Sph (Figure 16A and 16B). Treatment with 10µm-LR particles
resulted into loss of tumor integrity and enhanced anti-tumor activity with spheroid volume
of 5.6 ± 1.1 mm3 showing ~4.4 folds and 1.6 folds reduction in spheroid volume when
compared to 10µm-Sph (p<0.0001) and free DOX (p<0.05) respectively. These results
signify the shape dependent impact of particles on the anti-tumorigenic activity of DOX
against H69AR tumors with LR particles demonstrating the highest tumor growth
inhibition amongst all the treatment groups.
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Figure 17: Effect of single dose treatment on tumorigenic activity of H69AR cells grown
as 3D spheroids simulating in-vivo tumor conditions. (A) % Cell viability of spheroids
obtained using Cell-titer glo™ 3D calculated relative to untreated cells (control) considered
as 100%. Data represents mean±SD (n=3). (B) Representative florescent images of
spheroids after staining the live cells with calcein AM dye at the end of day 6.
****p<0.0001.

The 3D spheroids model represent a solid mass of tumor cells growing
exponentially in all the direction and therefore, optical imaging may not completely reflect
treatment’s efficiency. Therefore, % cell viability in 3D spheroids was performed to
determine % viable cells present in the tumor after the treatment period. Figure 17C
represents the % cell viability of 3D spheroids for each treatment group, wherein DOX
shows 24.2 ± 2.0 % viability in spheroids after 6 days. Treatment with 10µm-Sph,
demonstrated 65.1 ± 4.4 % viability while the stretched particles demonstrated significantly
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(p<0.0001) lower cell viability with 26.0 ± 2.1 % viability for 10µm-SR and 23.5 ± 3.1 %
viability for 10µm-LR (Figure 17C). These results indicate that treatment with the
stretched particles results into evident reduction in % viability compared to the spherical
particles. This data is also in accordance with the optical imaging data and tumor spheroid
volume establishing the particle shape effects against the 3D spheroids tumorigenic
activity.
To further validate the effectiveness of treatment groups against SCLC spheroids,
live cells present in the spheroids were imaged after staining with calcein AM dye
(providing green florescence). Figure 17D displays the florescent images of viable cells in
3D spheroids present in each treatment group. As can be inferred from the figure, control
has intense bright green florescence indicating the presence of live cells. Further, treatment
with DOX resulted into inhibition of the tumor growth when compared to control with
reduced viable cells being present in the spheroids. For 10µm-Sph, even though the size of
the spheroids was not significantly reduced, the florescence of the viable cells was
diminished (Figure 17D). This can be suggestive of the fact that 10µm-Sph may be able
to show cytotoxic effects without impacting the tumor size and the integrity of the
spheroids, however this effect was non-significant. On the contrary, treatment with rodshaped particles (10µm-SR and 10µm-LR) resulted into reduction in tumor size as well as
diminished florescence of viable cells compared to spherical particles indicating their
superior anti-tumorigenic activity (Figure 17D). These results are indicative of the fact
that particle shape does influence the tumorigenic action of H69AR cells in the in-vitro
simulation studies.
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Figure 18: Effect of multiple dose treatment on tumorigenic activity of H69AR cells grown
as 3D spheroids simulating in-vivo tumor conditions. (A) Representative images of
spheroids demonstrating suppression in tumor growth at days 0, 3 and 6. Scale bar = 200
µm (B) Quantitative representation of anti-tumor activity of treatment expressed as
spheroid volume (mm3) versus time (days) for multiple dose treatment. Data represent
mean±SEM (n = 6).
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B) In-vitro Tumor Simulation Studies- Multiple Dose
Multiple dose treatment revealed interesting results establishing the anti-tumor activity of
various treatment groups. As seen in Figure 18A, the control group demonstrated 6.8 folds
significant increase (p<0.001) in the tumor growth with 41.1 ± 3.4 mm3 spheroid volume
at day 6 when compared to the initial (day 0) tumor volume (Figure 18B). DOX treatment
resulted into inhibition of tumor growth and a significant (p<0.0001) 6.2 folds reduction
in spheroid volume (6.6 ± 2.2 mm3) as compared to control (Figure 18B). Additionally,
DOX also resulted into distortion of tumor integrity at Day 6 which is a characteristic antitumorigenic activity of chemotherapeutic agent (Figure 18A). Treatment with DOXconjugated particles demonstrated the influence of particle shape on the treatment
effectiveness. 10µm-Sph demonstrated significant (p<0.001) reduction of 1.5 folds in
spheroid volume with 27.5 ± 3.7 mm3 when compared to control. This effect was found to
be more pronounced with treatment of rod-shaped particles 10µm-SR particles
demonstrated a significant (p<0.0001) 7.0 folds reduction in spheroid growth with a tumor
volume of 5.9 ± 0.5 mm3 as against control and ~5.0 folds reduction when compared to
spherical particles (Figure 18A and 18B). Treatment with 10µm-LR particles resulted into
5.6 ± 1.1 mm3 spheroid volume as in Figure 18B demonstrating a significant (p<0.0001)
5.0 folds reduction as against 10µm-Sph. In addition to reduction in tumor growth and
spheroid volume, it was interesting to observe that the rod-shaped particles impacted the
tumor integrity which was found to be absent in the spherical particles . These results may
be suggestive of the fact that rod-shaped particles possess better anti-tumorigenic activity
against H69AR cells when compared to spherical particles.
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(A)

(B)

Figure 19: Effect of multiple dose treatment on tumorigenic activity of H69AR cells grown
as 3D spheroids simulating in-vivo tumor conditions. (A) % Cell viability of spheroids
obtained using Cell-titer Glo™ 3D calculated relative to untreated cells (control)
considered as 100%. Data represents mean±SD (n=3). (B) Representative florescent
images of spheroids after staining the live cells with calcein AM dye at the end of day 6.
*p<0.05 and ****p<0.0001.

% Cell viability of 3D spheroids for each treatment group was analyzed using
luminescence to further support the data of microscopic imaging. As seen in Figure 19A,
DOX demonstrated 22.7 ± 1.7% cell viability after 6 days. Upon evaluating DOXconjugated particles, shape dependent effect was predominantly observed with spherical
particles demonstrating the lowest % viability with 59.7 ± 2.5 % while rod-shaped particles
resulted into significant (p<0.0001) 3 folds reduction in viability with ~20 % cell viability.
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Furthermore, treatment with 10µm-SR and 10µm-LR particles also resulted into significant
(p<0.05) reduction in % cell viability as compared to free DOX. These results are in
accordance with the tumor imaging and spheroids volume data signifying the importance
of particle shape in improving the efficacy of treatment.
The viable cells in the 3D spheroids were stained with calcein AM dye, to
understand the therapeutic behavior of treatment groups by imaging the viable cells and
further validate the microscopic and luminescence data. As seen in the Figure 19B, control
group displays bright green florescence indicating the presence of viable cells. Treatment
with DOX resulted into reduction in the tumor size and the viable cells florescence as
compared to control. Particle shape dependent effect on tumorigenic activity of H69AR
spheroids was analyzed using 10µm-Sph, 10µm-SR, and 10µm-LR particles. The spherical
particles indicated minimal reduction in the tumor size amongst the conjugated DOX
particles (Figure 19B). However, the florescence of viable cells in the 10µm-Sph treatment
was found to be diminished indicating that the spherical particles does show cytotoxicity
without impacting the tumor integrity. Treatment with both the rod-shaped particles
demonstrated reduction in tumor size unlike the spherical particles. Additionally, the
florescence of the viable cells in both the groups was found to be diminished compared to
free DOX treated spheroids (Figure 19B). These findings indicate the pronounced
effectiveness of the particles upon changing the shape from spherical to rod-shape, thereby
imparting better therapeutic activity.
The results of in-vitro tumor simulation studies establish the superior antitumorigenic activity of rod-shaped particles against spheres which may be suggestive of
better penetrability of rod-shaped particles in the 3D spheroids. However, increase in AR
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of rod-shaped particles did not significantly influence the penetrability in the spheroids as
can be seen for SR and LR which are in accordance with previously reported studies
[115,116]. Studies performed by Chauhan et al., demonstrated 1.7 folds improvement in
penetration of nanorods against spherical counterparts evaluated in orthotopic E0771
mammary tumors. Similarly, Black et al., performed in-vivo studies to evaluate the efficacy
of various particle shape of radiolabeled silver nanoparticles (rods, disks, spheres, and
cube)in penetrating the solid tumor upon intravenous administration. It was reported that
rods and cube shaped particles penetrated to the core of tumor while the disk- and sphereshaped particles were predominantly located at the rim of the tumor [117]. These studies
have reported the internalization of nanosized particles which may be internalized via
mechanisms such as diffusion, endocytosis, or pinocytosis while the particles used in our
project are micron-sized which are extensively internalized via phagocytosis wherein again
the influence of shape has been severely signified [60,118]. The results of in-vitro tumor
simulation therefore establish the improved effectiveness of treatment by change of particle
shape form sphere to rod-shape.
4.9 Investigating Impact on Cardiotoxicity
Therapeutic use of DOX has been limited owing to its adverse side effects amongst
which deposition of cumulative dose causes cardiotoxicity [119]. Clinically induced DOX
cardiotoxicity leads to development of cardiomyopathy subsequently causing apoptosis
and necrosis of cardiomyocytes leading to progressive cardiac failure [120]. Several
mechanisms have been identified for development of DOX induced cardiotoxicity such as
reactive oxygen species production, apoptosis, DNA damage, lipid peroxidation and
autophagy [69]. As particle shape has shown to influence the internalization of particles in
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normal cells like macrophages, with minimal uptake of high AR particles, we hypothesized
that conjugation of DOX to rod shaped particles may result into reduced cardiotoxic
activity of DOX due to reduced uptake.
4.9.1 Cytotoxic Assessment on Cardiomyoblasts
The viability of H9c2 rat cardiomyoblasts cells was analyzed using MTT assay after 24
hours of exposure to various treatment groups as shown in Figure 20A. As seen from the
figure, DOX displayed dose dependent toxicity against H9c2 cells and the IC50 value of
DOX was found to be 37.1 ± 3.0 µM which is in accordance with the IC 50 value reported
in literature. Treatment with 10µm-Sph displayed 1.6 folds reduction (p<0.001)

in

cytotoxicity as compared to free DOX with 61.1 ± 7.2 % cell viability observed at 40 µM
concentration, the highest concentration tested. Both the rod-shaped particles, 10µm-SR
and 10µm-LR also demonstrated a significant (p<0.0001) reduction in the cytotoxicity as
compared to the free DOX (Figure 20A). The % cell viability after treatment with 10µmSR particles was found to be 78.0 ±9.3 % cell viability while 10µm-LR particles showed
80.3 ± 6.1 % cell viability at 40 µM concentration. These results clearly show that DOXconjugated particles resulted into lower cytotoxic effects against H9c2 cells. Amongst the
DOX-conjugated particles, change in the shape of particle to rod-shape further resulted into
lower cytotoxicity as compared to the spherical particles.
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(A)

(B)

(C)

Figure 20: Influence of cardiotoxicity of DOX and DOX-conjugated particles after
treatment of H9c2 cardiomyoblasts. (A) Cytotoxic potential of treatment groups evaluated
after 24 hrs. treatments and expressed as % cell viability (n=6 for 3 individual
experiments). (B) Apoptosis effect of free DOX and DOX-conjugated particles evaluated
using Realtime-Glo™ expressed as luminescence intensity (n=6) and (C) Representative
florescence images of H9c2 cardiomyoblasts stained by AO/EB staining. Data represents
mean±SD. ** p<0.01 and *** p<0.001.
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4.9.2 Lactate Dehydrogenase (LDH) Assay
LDH is a cytosolic enzyme released upon damage to the cell membrane and is well
known marker of cell death or cell damage. Cell injury to H9c2 cardiomyoblasts after
treatment for 24 hours was evaluated by measuring the LDH release in the media using the
Promega Luminescence kit. As seen in Figure 20B free DOX (1.25 µM) induces the
highest increase in the luminescence signal amongst all the treatment groups suggesting
significant (p<0.001) LDH leakage in cell culture supernatant following 24 hours
incubation. Therefore, indicating that exposure to free DOX resulted in significant damage
to cell membrane. However, treatment with DOX-conjugated 10µm-Sph particles
displayed a significant (p<0.01) reduction in the LDH release from H9c2 cells.
Furthermore, incubation of cardiomyoblasts with rod-shaped particles i.e., 10µm-SR and
10µm-LR resulted into 2.0 folds significant (p<0.001) reduction in the LDH activity as
compared to free DOX (Figure 20B). The LDH activity of the DOX-conjugated particles
were almost like the control indicating the role of microparticles in reducing the
cardiotoxicity of free DOX. This can be attributed to the conjugation of DOX to
polystyrene particles via a stable amide linkage which prevents DOX to be readily
available. The small increase in LDH activity observed for 10µm-Sph compared to 10µmSR and 10µm-LR particles may be because of preferential internalization of spherical
particles against the rod-shaped particles like macrophages.
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4.9.3 Apoptosis Evaluation in H9c2 cells
Several in-vitro and in-vivo studies have reported that DOX induces apoptosis in
the cardiomyocytes, thereby indicating that apoptosis is major pathway leading to cardiac
dysfunction and eventually cardiac failure in patients. Figure 20C demonstrates the effect
of free DOX and DOX-conjugated particles on the apoptosis induced damage in H9c2
cardiomyocytes using acridine orange (AO)/ethidium bromide (EB) staining. Ethidium
bromide enters the cell with compromised cell membrane integrity and stains the cells with
red or orange fluorescence indicating the induction of apoptosis eventually causing cell
death. The results demonstrate that exposure of cells to free DOX resulted into reduced cell
viability and staining of the cells with red color indicating the presence of non-viable cells
[69]. Treatment with all the DOX-conjugated particles showed absence of red/orangestained cells indicating absence of cytotoxic effects on the H9c2 cardiomyocytes (Figure
20C). These results are in corroboration with the cytotoxicity and LDH activity assay
further confirming the diminished activity of DOX upon being conjugated to the
polystyrene particles.
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5.0 Conclusion
In this project we demonstrated the interplay between the particle size and particle
shape on the aerodynamic properties using NGI. Our results showed that change in the
particle shape from spherical to rod-shaped display improved aerodynamic behavior of
particles and this effect was amplified amongst particles with large equivalent diameter.
Subsequently, we have assessed the influence of particle shape on escape of phagocytic
uptake by macrophages wherein rod-shape particles displayed reduced uptake compared
to spherical particles and this effect being higher for elongated particles having higher AR
value. The current study also provides evidence about particle shape influence on the
effectiveness of treatment against SCLC cells. Results demonstrated superior cytotoxic
activity of rod-shaped particles against spherical particles. Importantly, these results were
further validated using in-vitro tumor simulation studies wherein the rod-shaped particles
have pronounced effect in inhibiting the tumor growth and distorting the tumor integrity
which would help translation to preclinical settings. Furthermore, we have evaluated the
particle shape effect on cardiotoxicity of DOX using DOX-conjugated in cardiomyoblasts.
Results confirmed that elongated rod-shaped particles illustrated diminished cardiotoxicity
on cells when compared to their spherical counterparts. Therefore, our findings provide
valuable insights about particle shape influence on designing inhalable delivery carriers for
pulmonary administration to combat respiratory diseases.
Since this proof-of-concept study was performed using polystyrene particles which
are non-biodegradable, the translation to preclinical setting remains challenging.
Therefore, future studies may involve developing biodegradable particles of various shapes
and evaluate their impact on pulmonary deposition behavior. Moreover, the existing rod69

shaped particles can be conjugated with other small molecules or large molecules such as
targeting proteins. This strategy can be further translated to fabricate other biodegradable
rod-shaped particles with tunable surface modifications for providing desired therapeutic
effects. The biodegradable particles can be conjugated with variety of therapeutics or can
be passively loaded with drug molecules of interest. In-vivo studies can be performed in
orthotopic lung tumor model to further validate the influence of particle shape on the
aerosolization efficiency and the therapeutic activity, thereby designing optimized delivery
carriers for pulmonary drug delivery.
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